ASK REDCHAT ANYTHING ABOUT GENPREX INC.
Genprex Inc. (NASDAQ: GNPX)
Listen to this Section
$0.64
-0.0520
(
-7.48% )
249.8K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| REQORSA (quaratusugene ozeplasmid) + TagrissoDetailsLung cancer, Non-small cell lung carcinoma, Cancer |
Phase 2a |
| REQORSA (quaratusugene ozeplasmid) + KeytrudaDetailsCancer, Non-small cell lung carcinoma, Lung cancer |
Phase 1/2 |
| REQORSA (quaratusugene ozeplasmid) + TecentriqDetailsLung cancer, Cancer, Small cell lung cancer |
Phase 1/2 |
Market Data
| Open |
$0.64 |
| Previous Close |
$0.70 |
| Volume |
249.8K |
| Market Cap |
$7.62M |
| Day Range |
$0.64 - $0.73 |
| 52 Week Range |
$0.64 - $55.00 |
| Shares Outstanding |
10.59M |
| Change % |
-7.48% |
| Net Change |
▼ -0.0520 |
| Insider Ownership |
-0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2018 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-5,087.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-02-21 |
Sale |
-1126.00 |
Confer Ryan M. |
| 2024-02-21 |
Sale |
-2642.00 |
Varner John Rodney |
| 2024-02-21 |
Sale |
-1319.00 |
Berger Mark Stanley |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 10-q |
Quarterly Reports |
49 |
Nov 14, 2025 |
| s-8 |
Registration statements |
15 |
Nov 14, 2025 |
| 424b5 |
Other |
2 |
Nov 10, 2025 |
| 8-k |
8K-related |
13 |
Nov 04, 2025 |
| 8-k |
8K-related |
19 |
Oct 29, 2025 |
| 8-k |
8K-related |
13 |
Oct 28, 2025 |
| 8-k |
8K-related |
19 |
Oct 24, 2025 |
| 8-k |
8K-related |
13 |
Oct 23, 2025 |
| 8-k |
8K-related |
13 |
Oct 21, 2025 |
| 8-k |
8K-related |
77 |
Oct 17, 2025 |